The use of vaccines have resulted in a remarkable improvement in global health. It has
saved several lives, reduced treatment costs and raised the quality of animal and human …

Correlates of protection (CoPs) are increasingly important in the development and licensure
of vaccines. Although the study of CoPs was initially directed at identifying a single immune …

Background More than 1· 8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …

Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …

HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant
adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered …

Despite major advances in our understanding of the biology of HIV-1 infection, and
advances in antiretroviral therapy to treat the disease, there were 2.1 million new cases of …

Introduction: Given the complexities of HIV infection and the HIV genetic heterogeneity, a
successful HIV vaccine should elicit broad adaptive and innate immune responses. Vaccine …

Introduction: Adjuvants form an integral component in most of the inactivated and subunit
vaccine formulations. Careful and proper selection of adjuvants helps in promoting …

Despite 30 years of effort, we do not have an effective HIV-1 vaccine. Over the past decade,
the HIV-1 vaccine field has shifted emphasis toward antibody-based vaccine strategies …

We compare immunogenicity and protective efficacy of an HIV vaccine comprised of env and
gag DNA and Env (Envelope) proteins by co-administration of the vaccine components in …